Currently out of the existing stock ratings of Jason Mccarthy, 300 are a BUY (84.51%), 55 are a HOLD (15.49%).

Jason Mccarthy

Work Performance Price Targets & Ratings Chart

Analyst Jason Mccarthy, currently employed at MAXIM GROUP, carries an average stock price target met ratio of 50.93% that have a potential upside of 57.38% achieved within 377 days.

Jason Mccarthy’s has documented 650 price targets and ratings displayed on 106 stocks. The coverage is on Healthcare, Consumer Defensive, Technology, Energy, Consumer Cyclical, Financial Services sectors.

Most recent stock forecast was given on CAPR, Capricor Therapeutics at 31-Jul-2026.

Wall Street Analyst Jason Mccarthy

Analyst best performing recommendations are on ONTX (ONCONOVA THERAPEUTICS).
The best stock recommendation documented was for CAPR (CAPRICOR THERAPEUTICS) at 9/17/2024. The price target of $12 was fulfilled within 13 days with a profit of $6.92 (136.22%) receiving and performance score of 104.78.

Average potential price target upside

of $1864.95 (95.61%) on KTRA (KINTARA THERAPEUTICS).
of $548.12 (43.02%) on BLUE (BLUEBIRD BIO).
of $99.67 (83.11%) on TCON (TRACON PHARMACEUTICALS).

ABEO Abeona Therapeutics ADMA ADMA Biologics ADMP Adamis Pharma AGEN Agenus AMYT Amryt Pharma Holdings Ltd ARTL Artelo Biosciences ATNF 180 Life Sciences Corp ATOS Atossa Genetics BCLI Brainstorm Cell Therapeutics BGNE BeiGene Ltd BLFS BioLife Solutions BLRX BioLineRx Ltd BLUE Bluebird bio BTX Brooklyn Immunotherapeutics CAPR Capricor Therapeutics CFRX ContraFect Corp CHRS Coherus BioSciences CODX Co-Diagnostics ENTX Entera Bio Ltd GILD Gilead Sciences GLMD Galmed Pharmaceuticals Ltd GOVX GeoVax Labs HTBX Heat Biologics IMMP Immutep Ltd ADR INO Inovio Pharmaceuticals KZIA Kazia Therapeutics Ltd ADR MESO Mesoblast Ltd MTNB Matinas BioPharma Holdings OMER Omeros ONTX Onconova Therapeutics PRTO Proteon Therapeutics SAVA Cassava Sciences SCYX Scynexis SLS Sellas Life Sciences Group TARA Protara Therapeutics TTNP Titan Pharmaceuticals VKTX Viking Therapeutics VRTX Vertex Pharmaceuticals VTGN VistaGen Therapeutics ADIL Adial Pharmaceuticals MNMD Mind Medicine ACXP Acurx Pharmaceuticals LLC ANVS Annovis Bio BIOC Biocept CYTH Cyclo Therapeutics DMAC DiaMedica Therapeutics FENC Fennec Pharmaceuticals GLPG Galapagos NV ADR INDP Indaptus Therapeutics KTRA Kintara Therapeutics MNPR Monopar Therapeutics NHWK Nighthawk Biosciences NLSP NLS Pharmaceutics AG NTEC Intec Pharma Ltd PBLA Panbela Therapeutics RDUS Schnitzer Steel Industries RVPH Reviva Pharmaceuticals Holdings SNPX Synaptogenix UNCY Unicycive Therapeutics BNGO Bionano Genomics PSTV Plus Therapeutics BNOX Bionomics Ltd ADR FEMY Femasys TCON TRACON Pharmaceuticals INVO INVO Bioscience MBRX Moleculin Biotech BLTE Belite Bio ADR CMPS Compass Pathways Plc RZLT Rezolute CNSP Cns Pharmaceuticals RNXT RenovoRx AIM AIM ImmunoTech AZRX AzurRx BioPharma CLRB Cellectar Biosciences CNTX Context Therapeutics CRDF Cardiff Oncology CTXR Citius Pharmaceuticals FWBI First Wave BioPharma INMB INmune Bio ONCS OncoSec Medical ONCY Oncolytics Biotech SNGX Soligenix VYNT Vyant Bio GANX Gain Therapeutics MNOV MediciNova ACHV Achieve Life Sciences ADM Archer-Daniels-Midland Company AI C3 Ai AM Antero Midstream Partners LP AP Ampco-Pittsburgh ARM Arm Holdings plc American Depositary Shares ATAI ATAI Life Sciences BV BC Brunswick BCDA Biocardia BL Blackline CFR Cullen/Frost Bankers GNLX Genelux Common Stock IDXG Interpace Biosciences LCTX Lineage Cell Therapeutics NL NL Industries ON ON Semiconductor SA Seabridge Gold SPHS Sophiris Bio SY So-Young International VIRI Virios Therapeutics Llc ATNM Actinium Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)